Cantor Fitzgerald Forecasts VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Verve Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will post earnings per share of ($2.67) for the year. The consensus estimate for Verve Therapeutics' current full-year earnings is ($2.49) per share.

Several other research firms also recently weighed in on VERV. Royal Bank of Canada lowered their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. HC Wainwright lowered their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 6th.

Verve Therapeutics Price Performance

Shares of VERV stock traded up $1.05 during mid-day trading on Wednesday, hitting $7.62. The stock had a trading volume of 1,745,194 shares, compared to its average volume of 1,457,244. Verve Therapeutics has a 12-month low of $4.30 and a 12-month high of $19.34. The firm's 50-day moving average is $5.80 and its two-hundred day moving average is $5.77. The firm has a market capitalization of $645.36 million, a P/E ratio of -3.13 and a beta of 1.68.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.11. The firm had revenue of $6.87 million during the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company's revenue was up 120.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.72) earnings per share.

Institutional Trading of Verve Therapeutics

Several hedge funds have recently modified their holdings of VERV. GAMMA Investing LLC raised its stake in shares of Verve Therapeutics by 189.7% during the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock worth $34,000 after acquiring an additional 3,964 shares in the last quarter. Creative Planning acquired a new position in shares of Verve Therapeutics during the third quarter worth $50,000. PFG Investments LLC acquired a new position in shares of Verve Therapeutics during the third quarter worth $53,000. Erste Asset Management GmbH purchased a new stake in shares of Verve Therapeutics during the 3rd quarter valued at $56,000. Finally, Impact Partnership Wealth LLC acquired a new stake in shares of Verve Therapeutics in the 4th quarter worth $70,000. 97.11% of the stock is owned by hedge funds and other institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.